XSHE300206
Market cap833mUSD
Jan 10, Last price
10.26CNY
1D
-3.02%
1Q
-1.91%
Jan 2017
8.00%
IPO
66.49%
Name
Edan Instruments Inc
Chart & Performance
Profile
Edan Instruments, Inc. engages in the research, development, manufacture, and sale of medical equipment worldwide. The company offers diagnostic electrocardiograph (ECG) products, including resting ECG, stress test, holter, wireless solution, and ECG workstation products; patient monitoring systems, such as vital signs, transport, and central monitoring systems, as well as high acuity cares, acute and sub-acute cares, telemetry, and pulse oximetry products; and obstetrics and gynecology products comprising fetal and maternal monitoring systems, fetal telemetry systems, ultrasonic doppler systems, and video colposcopes. It also provides ultrasound imaging systems that include color doppler ultrasound and B/W digital ultrasound systems; and in-vitro diagnostics, which comprise hematology analyzers. In addition, the company offers point-of-care testing systems, including blood gas and chemistry, magnetic immunoassay, and colloidal gold-labeled immunoassay analyzers; and veterinary ultrasound, ECG, ABG, and monitoring products. Edan Instruments, Inc. is headquartered in Shenzhen, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 1,937,989 11.22% | 1,742,412 6.48% | |||||||
Cost of revenue | 1,389,733 | 1,472,975 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 548,256 | 269,437 | |||||||
NOPBT Margin | 28.29% | 15.46% | |||||||
Operating Taxes | (128) | 11,171 | |||||||
Tax Rate | 4.15% | ||||||||
NOPAT | 548,384 | 258,266 | |||||||
Net income | 221,301 -5.00% | 232,942 0.65% | |||||||
Dividends | (119,990) | (119,990) | |||||||
Dividend yield | 2.03% | 1.72% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 5,211 | ||||||||
Long-term debt | 22,180 | 10,375 | |||||||
Deferred revenue | 21,047 | 21,573 | |||||||
Other long-term liabilities | 1 | 2 | |||||||
Net debt | (966,703) | (988,294) | |||||||
Cash flow | |||||||||
Cash from operating activities | 153,961 | 335,158 | |||||||
CAPEX | (51,096) | ||||||||
Cash from investing activities | (48,029) | 64,197 | |||||||
Cash from financing activities | |||||||||
FCF | 391,294 | 302,242 | |||||||
Balance | |||||||||
Cash | 941,711 | 957,004 | |||||||
Long term investments | 47,173 | 46,876 | |||||||
Excess cash | 891,984 | 916,760 | |||||||
Stockholders' equity | 1,700,407 | 1,588,327 | |||||||
Invested Capital | 1,104,026 | 947,384 | |||||||
ROIC | 53.46% | 25.63% | |||||||
ROCE | 27.44% | 14.43% | |||||||
EV | |||||||||
Common stock shares outstanding | 579,683 | 579,683 | |||||||
Price | 10.21 -15.13% | 12.03 -14.56% | |||||||
Market cap | 5,918,567 -15.13% | 6,973,591 -14.29% | |||||||
EV | 4,951,864 | 5,985,297 | |||||||
EBITDA | 601,277 | 324,330 | |||||||
EV/EBITDA | 8.24 | 18.45 | |||||||
Interest | 2,040 | 1,581 | |||||||
Interest/NOPBT | 0.37% | 0.59% |